New hope for lung cancer patients: drug combo targets resistant tumors
NCT ID NCT07193160
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 23 times
Summary
This study tests a combination of two drugs (sacituzumab tirumotecan and furmonertinib) in 45 adults with advanced non-small cell lung cancer that has a specific gene mutation (EGFR) and has stopped responding to the first treatment. The goal is to see if the combo can shrink tumors or slow disease progression. Participants will receive the drugs and be monitored for side effects and how long the benefit lasts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.